Common questions about Vaxigrip (FAQ)
Q: What specific strains of virus are usually included in Vaxigrip?
A: The Vaxigrip Quadrivalent formula typically includes antigens from four strains of inactivated influenza virus. This includes two Type A subtypes and two Type B types, which are selected annually based on global surveillance and recommendations from the World Health Organization (WHO).
Q: How long is Vaxigrip considered effective or protective?
A: According to official information, it generally takes about two to three weeks after vaccination for the body to establish its protective immune response. Protection from the vaccine is limited, and annual administration is typically the schedule described in the product information because circulating viral strains often change each year.
Q: Why do some people feel ill after getting Vaxigrip?
A: Temporary symptoms like headache, muscle ache, fever, or a general feeling of being unwell (malaise) are documented in clinical studies. These are classified as very common or common side effects and usually resolve on their own within one to three days. These effects are temporary signs that the body's immune system is responding to the vaccine.
Q: Can I receive Vaxigrip if I have an autoimmune condition?
A: Official information indicates that people who are immunocompromised, such as those receiving immunosuppressant treatment, may have a diminished or reduced immune response to the vaccine. Regulatory documents note that the use of the vaccine depends on a complete assessment of individual circumstances.
Q: Does Vaxigrip interact with common pain relievers like ibuprofen or paracetamol?
A: The regulatory label does not formally list any specific non-vaccine medicine or substance, including common pain relievers, as a contraindicated combination. Official product information states that no formal clinical studies have been performed specifically with these types of medicinal products.
Q: Does Vaxigrip interact with blood thinners?
A: The product information states that caution is necessary during administration for people with a bleeding disorder or thrombocytopenia due to the risk of bleeding or bruising following the injection. There is no specific drug-to-drug (pharmacological) interaction listed in the regulatory texts.
Q: Are there any preservatives in Vaxigrip?
A: Trace amounts of components like neomycin or formaldehyde may be present as residuals from the manufacturing process. The pre-filled syringe presentation of Vaxigrip Tetra is described as thiomersal-free (mercury-free).
Q: Does Vaxigrip protect against all types of flu viruses?
A: The vaccine is prepared to provide protection against the four specific strains of influenza virus from which it is manufactured. Official product information indicates that the vaccine may not protect against all possible strains or types of influenza virus, nor does it protect against other respiratory illnesses like the common cold.
Q: What is the benefit of the quadrivalent formula versus the old trivalent formula?
A: The quadrivalent formula provides coverage against two influenza A subtypes and two influenza B types. This provides broader coverage compared to the older trivalent formula, which typically only includes one B virus type.
Q: What does 'haemagglutinin' mean in the description of Vaxigrip?
A: Haemagglutinin is one of the active substances in the vaccine. It is a protein found on the surface of the influenza virus used by the body to build a protective immune response.
Q: Why is Vaxigrip generally given as an injection, not a nasal spray?
A: Vaxigrip is an inactivated vaccine, meaning the virus is not live. This type of formulation is supplied as a suspension for injection and is designed to be administered into the muscle (intramuscular) or under the skin (subcutaneous) to ensure the correct immune response is developed.
Q: Is Vaxigrip approved in multiple countries, and are the formulas the same?
A: Vaxigrip is a globally established brand, and the selection of viral strains used in the vaccine is guided by the annual recommendations of the World Health Organization (WHO). This ensures that the viral components are relevant to the circulating strains determined globally.
Q: Can Vaxigrip be received by someone with a severe needle phobia?
A: The vaccine is most commonly administered by the intramuscular (IM) route, but the regulatory documents also permit the subcutaneous (SC) route. Official product information states that both the intramuscular (IM) route and the subcutaneous (SC) route are permitted for administration.
Q: What does the term 'seasonal prophylaxis' mean for Vaxigrip?
A: This term means that the vaccine is used for active immunisation, or protection, against influenza disease. The term 'seasonal' refers to the fact that influenza activity occurs primarily during specific, recognized seasons.
Q: Does the efficacy of Vaxigrip vary depending on the patient's age?
A: Clinical trials have been conducted across all age groups, including children, adults, and older adults. Studies indicate that the observed biological response to the vaccine may show different patterns between various age cohorts.
Q: Is it possible to receive Vaxigrip too early or too late in the season?
A: Vaccination is typically suggested before the start of the influenza season. Public health guidance notes that receiving the vaccination much earlier than the start of the season may result in reduced protection later in the season. Similarly, receiving it late may mean that the immune response is not fully developed before peak influenza activity occurs.
Q: What should I know about the manufacturing or testing of Vaxigrip?
A: Vaxigrip is described as a split-virion, inactivated vaccine. The manufacturing process involves inactivating the virus and purifying its surface fragments, called antigens, to ensure the finished product cannot cause influenza disease.
Q: Can Vaxigrip be used by healthcare workers?
A: Vaxigrip is officially indicated for use in adults and children from 6 months of age and older. The prescribing information includes no specific restrictions on the use of the vaccine by healthcare workers.
Q: What is the official definition of a serious reaction to Vaxigrip?
A: A serious adverse reaction is formally defined by regulatory agencies as one that results in death, is life-threatening, requires hospitalisation, results in significant disability or incapacity, or is a birth defect.
Q: What is the purpose of the 'adjuvant' mentioned in some vaccine descriptions?
A: An adjuvant is an additional substance sometimes used in vaccines to help enhance or boost the body’s immune response to the active ingredients. Vaxigrip Tetra is a standard-dose vaccine and does not contain an adjuvant.
Q: What is the difference between Vaxigrip and the high-dose versions of flu medicines?
A: Vaxigrip is considered a standard-dose vaccine. High-dose vaccines are available and typically contain four times the amount of the active ingredient per viral strain. High-dose versions are generally specifically indicated for older adults.
Q: Why do official sources recommend getting Vaxigrip early in the season?
A: The product label or guidance notes that administration is typically suggested early in the season to allow sufficient time (about two to three weeks) for the body to develop a full immune response. This ensures the protection is in place before the seasonal influenza activity typically begins.
Q: What official body monitors the safety of Vaxigrip after it is distributed?
A: Drug agencies, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), continuously monitor the safety of Vaxigrip. This is done through official post-marketing surveillance and vigilance systems that collect information after the drug is distributed.
Q: What is the official reporting process if someone suspects a side effect from Vaxigrip?
A: The official process for reporting suspected side effects is managed by the national regulatory authority in each region (for example, MedWatch in the US). The product information instructs individuals to contact a healthcare professional or pharmacist if they suspect a side effect.
Q: Why are there certain ingredients in Vaxigrip listed as 'trace amounts'?
A: Trace components, such as egg proteins, neomycin, formaldehyde, and octoxinol-9, are listed because they are used in the vaccine's manufacturing process. These ingredients may remain in minute, residual quantities in the final product.
